Free Trial
NASDAQ:QNCX

Quince Therapeutics Q1 2026 Earnings Results & Report

Quince Therapeutics logo
$31.73 0.00 (0.00%)
As of 10/13/2026

Quince Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 11, 2026. The company reported EPS of -$0.59 versus the -$26.00 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Quince Therapeutics EPS Results

Actual EPS
-$0.59
Consensus EPS
-$26.00
Beat/Miss
Beat by +$25.41
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

Quince Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Quince Therapeutics Q1 2026 Earnings FAQ

Quince Therapeutics (NASDAQ:QNCX) reported earnings of -$0.59 per share for Q1 2026, beating the consensus estimate of -$26.00. The report was announced on Monday, May 11, 2026.

Quince Therapeutics Earnings Headlines

Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
See More Quince Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Quince Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Quince Therapeutics and other key companies, straight to your email.

About Quince Therapeutics

Quince Therapeutics (NASDAQ:QNCX) is a biotechnology company focused on developing treatments for rare diseases. Its principal program has been EryDex, an investigational therapy designed to deliver dexamethasone sodium phosphate inside a patient’s own red blood cells.

The company developed EryDex for ataxia-telangiectasia, a rare inherited disorder that can cause progressive neurological and immune-system problems. The treatment uses a process intended to load the drug into red blood cells for gradual release. Quince’s program followed its 2023 combination with EryDel, the company that developed the EryDex technology.

EryDex was evaluated in a Phase 3 clinical trial, which did not meet its primary efficacy endpoint. Quince is headquartered in the United States; its work on EryDex grew out of technology developed by EryDel in Europe.

View Quince Therapeutics Profile